Biopharmaceutical Major Takeda Biopharmaceuticals India Private Limited (Formerly Known As Baxalta Bioscience India Pvt. Ltd.) Has Launched Cinryze, An Innovative Injectable Prescription Medicine For The Treatment Of Hereditary Angioedema (Hae) Patients.With Eight Years Of Global Clinical Experience Proving Efficacy And Safety, Cinryze Has The Potential To Mark A Breakthrough In The Episodic Treatment, Short And Long-Term Prophylaxis For Hae.Moreover, Cinryze Is The Pioneer C1 Esterase Inhibitor (C1-I Nh) Approved By The Us Food And Drug Administration (Fda) And European Medicines Agency (Ema) For The Symptomatic Management Of Hae And For Preventing Future Angioedema Attacks.Cinryze Is Indicated In India For Routine Prevention (Prophylaxis) Of Angioedema Attacks In Adults, Adolescents And Children 6 Years Of Age And Above With Hae, Treatment Of Angioedema Attacks And Pre-Procedure Prevention Of Angioedema Attacks In Adults, Adolescents And Children 2 Years Of Age And Above With Hae.The Disease Is Usually Identified By Recurrent Episodes Of Fluid Accumulation Outside The Blood Vessels, Causing Rapid Swelling Of Body Tissues. The Symptoms Of Hae Could Be Like An Allergic Reaction; However, The Potential Outcome Could Be Life-Threatening In Case Of Hae. Due To The Lack Of Awareness Among Healthcare Professionals, Hae Is Highly Underdiagnosed In The Country.Speaking At The Launch, Serina Fischer, General Manager, Takeda Biopharmaceuticals India Private Limited Said,
